ADCT Fundamental Analysis - ADC THERAPEUTICS SA

Fundamental Rating

Overall ADCT gets a fundamental rating of 2 out of 10. We evaluated ADCT against 531 industry peers in the Biotechnology industry. Both the profitability and financial health of ADCT have multiple concerns. ADCT is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ADCT has reported negative net income.

ADCT had a negative operating cash flow in the past year.

ADCT had negative earnings in each of the past 5 years.

In the past 5 years ADCT always reported negative operating cash flow.

1.2 Ratios

ADCT has a Return On Assets of -57.61%. This is comparable to the rest of the industry: ADCT outperforms 43.36% of its industry peers.

		Industry Rank	Sector Rank
ROA	-57.61%
ROE	N/A
ROIC	N/A

ROA(3y)-48.71%

ROA(5y)-46.26%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With an excellent Gross Margin value of 92.73%, ADCT belongs to the best of the industry, outperforming 92.90% of the companies in the same industry.

ADCT's Gross Margin has declined in the last couple of years.

The Profit Margin and Operating Margin are not available for ADCT so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	92.73%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-1.51%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ADCT does not have a ROIC to compare to the WACC, probably because it is not profitable.

ADCT has more shares outstanding than it did 1 year ago.

ADCT has more shares outstanding than it did 5 years ago.

The debt/assets ratio for ADCT is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -7.61, we must say that ADCT is in the distress zone and has some risk of bankruptcy.

ADCT has a Altman-Z score of -7.61. This is in the lower half of the industry: ADCT underperforms 69.53% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-7.61

ROIC/WACCN/A

WACC4.53%

2.3 Liquidity

ADCT has a Current Ratio of 4.63. This indicates that ADCT is financially healthy and has no problem in meeting its short term obligations.

ADCT has a Current ratio of 4.63. This is comparable to the rest of the industry: ADCT outperforms 52.15% of its industry peers.

ADCT has a Quick Ratio of 4.34. This indicates that ADCT is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of ADCT (4.34) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	4.63
Quick Ratio	4.34

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ADCT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.35%, which is quite impressive.

The Revenue for ADCT has decreased by -39.09% in the past year. This is quite bad

Measured over the past years, ADCT shows a very strong growth in Revenue. The Revenue has been growing by 98.48% on average per year.

EPS 1Y (TTM)44.35%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%28.57%

Revenue 1Y (TTM)-39.09%

Revenue growth 3Y27.85%

Revenue growth 5Y98.48%

Sales Q2Q%-11.03%

3.2 Future

ADCT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.39% yearly.

ADCT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 33.94% yearly.

EPS Next Y12.63%

EPS Next 2Y14.62%

EPS Next 3Y15.39%

EPS Next 5YN/A

Revenue Next Year5.27%

Revenue Next 2Y4.57%

Revenue Next 3Y26.8%

Revenue Next 5Y33.94%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ADCT. In the last year negative earnings were reported.

Also next year ADCT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ADCT's earnings are expected to grow with 15.39% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y14.62%

EPS Next 3Y15.39%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ADCT does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ADC THERAPEUTICS SA

NYSE:ADCT (12/5/2025, 8:04:00 PM)

After market: 3.39 +0.1 (+3.04%)

3.29

-0.25 (-7.06%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-10 2025-11-10/bmo

Earnings (Next)03-25 2026-03-25/amc

Inst Owners53.82%

Inst Owner Change-0.59%

Ins Owners5.27%

Ins Owner Change-0.21%

Market Cap407.57M

Revenue(TTM)75.21M

Net Income(TTM)-166.94M

Analysts86.67

Price Target8.16 (148.02%)

Short Float %5.84%

Short Ratio6.41

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)20.04%

Min EPS beat(2)18.68%

Max EPS beat(2)21.4%

EPS beat(4)4

Avg EPS beat(4)20.88%

Min EPS beat(4)12.49%

Max EPS beat(4)30.94%

EPS beat(8)6

Avg EPS beat(8)-0.22%

EPS beat(12)7

Avg EPS beat(12)-2.22%

EPS beat(16)10

Avg EPS beat(16)1.26%

Revenue beat(2)1

Avg Revenue beat(2)-1.14%

Min Revenue beat(2)-5.69%

Max Revenue beat(2)3.41%

Revenue beat(4)2

Avg Revenue beat(4)3.11%

Min Revenue beat(4)-12.78%

Max Revenue beat(4)27.51%

Revenue beat(8)3

Avg Revenue beat(8)0.81%

Revenue beat(12)4

Avg Revenue beat(12)-4.76%

Revenue beat(16)7

Avg Revenue beat(16)2.72%

PT rev (1m)0%

PT rev (3m)-3.03%

EPS NQ rev (1m)13.86%

EPS NQ rev (3m)12.12%

EPS NY rev (1m)7.32%

EPS NY rev (3m)6.28%

Revenue NQ rev (1m)-1.91%

Revenue NQ rev (3m)0.37%

Revenue NY rev (1m)-1.27%

Revenue NY rev (3m)-2.08%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	5.42
P/FCF	N/A
P/OCF	N/A
P/B	N/A
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-1.33

EYN/A

EPS(NY)-1.13

Fwd EYN/A

FCF(TTM)-1.07

FCFYN/A

OCF(TTM)-1.06

OCFYN/A

SpS0.61

BVpS-1.92

TBVpS-1.92

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-57.61%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	92.73%
FCFM	N/A

ROA(3y)-48.71%

ROA(5y)-46.26%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-1.51%

GM growth 5YN/A

F-Score2

Asset Turnover0.26

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	-79.73%
Cap/Sales	0.47%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	4.63
Quick Ratio	4.34
Altman-Z	-7.61

F-Score2

WACC4.53%

ROIC/WACCN/A

Cap/Depr(3y)144.88%

Cap/Depr(5y)161.59%

Cap/Sales(3y)2.31%

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)44.35%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%28.57%

EPS Next Y12.63%

EPS Next 2Y14.62%

EPS Next 3Y15.39%

EPS Next 5YN/A

Revenue 1Y (TTM)-39.09%

Revenue growth 3Y27.85%

Revenue growth 5Y98.48%

Sales Q2Q%-11.03%

Revenue Next Year5.27%

Revenue Next 2Y4.57%

Revenue Next 3Y26.8%

Revenue Next 5Y33.94%

EBIT growth 1Y53.62%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-21.15%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y6.01%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y4.21%

OCF growth 3YN/A

OCF growth 5YN/A

ADC THERAPEUTICS SA / ADCT FAQ

Can you provide the ChartMill fundamental rating for ADC THERAPEUTICS SA?

ChartMill assigns a fundamental rating of 2 / 10 to ADCT.

What is the valuation status for ADCT stock?

ChartMill assigns a valuation rating of 0 / 10 to ADC THERAPEUTICS SA (ADCT). This can be considered as Overvalued.

Can you provide the profitability details for ADC THERAPEUTICS SA?

ADC THERAPEUTICS SA (ADCT) has a profitability rating of 1 / 10.

What is the financial health of ADC THERAPEUTICS SA (ADCT) stock?

The financial health rating of ADC THERAPEUTICS SA (ADCT) is 2 / 10.

ADC THERAPEUTICS SA (ADCT) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

ADC THERAPEUTICS SA / ADCT FAQ

Can you provide the ChartMill fundamental rating for ADC THERAPEUTICS SA?

What is the valuation status for ADCT stock?

Can you provide the profitability details for ADC THERAPEUTICS SA?

What is the financial health of ADC THERAPEUTICS SA (ADCT) stock?